CN109503688A - With the active nucleoside phosphorylase long-chain ester analogs of suppressing virus replication, preparation method and its medicinal usage - Google Patents

With the active nucleoside phosphorylase long-chain ester analogs of suppressing virus replication, preparation method and its medicinal usage Download PDF

Info

Publication number
CN109503688A
CN109503688A CN201811577370.6A CN201811577370A CN109503688A CN 109503688 A CN109503688 A CN 109503688A CN 201811577370 A CN201811577370 A CN 201811577370A CN 109503688 A CN109503688 A CN 109503688A
Authority
CN
China
Prior art keywords
long
chain ester
compound
nucleoside phosphorylase
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811577370.6A
Other languages
Chinese (zh)
Inventor
刘洪海
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Foshan University
Original Assignee
Foshan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foshan University filed Critical Foshan University
Priority to CN201811577370.6A priority Critical patent/CN109503688A/en
Publication of CN109503688A publication Critical patent/CN109503688A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

The invention discloses one group to have the active nucleoside phosphorylase long-chain ester analogs of suppressing virus replication, preparation method and its medicinal usage.Novel nucleoside phosphoric acid long-chain ester analogs disclosed by the invention are significantly superior to the Suo Feibuwei of clinical application in terms of anti-hepatitis activity, on chiral phosphorus atoms, long-chain alkoxy base alkyl-substituted phenyl, hydroxy substituted amino acid, cytotoxicity is significantly reduced in surveyed cell line, antiviral activity is improved, there is extraordinary potential applicability in clinical practice.

Description

With the active nucleoside phosphorylase long-chain ester analogs of suppressing virus replication, preparation method And its medicinal usage
Technical field
The invention belongs to pharmaceutical synthesis fields, and in particular to the preparation side of a kind of novel nucleoside phosphorylase long-chain ester analogs Method and its pharmaceutical composition and purposes, especially as the purposes for the treatment of hepatitis C.
Background technique
The patient that Hepatitis C Virus (HCV) has 3-4 million newly-increased every year, the World Health Organization estimate global The infected is more than 200,000,000, and in China more than 10,000,000 patients, HCV belongs to flaviviridae hepatovirus virus.Long-term hepatitis C Virus infection is gently to inflammation, weight to cirrhosis, liver cancer.
Initially the method for the treatment of HCV infection is interferon and interferon and ribavirin combination therapy, only 50% is controlled Treatment person has a reaction to this method, and interferon has an apparent side effect, for example, flu-like symptoms, weight lower and Fatigue and weak, and interferon and ribavirin combination therapy then generate sizable side effect, including haemolysis, anemia and tired Deng.
Hepatitis C pathogenesis is fully aware of not yet, causes liver cell structure and function when HCV is replicated in liver cell Change or interference Hepatocyte synthesizes, degeneration of liver cells can be caused downright bad, show that HCV directly damages liver, cause to fall ill Certain effect.
U.S. FDA had approved multiple HCV drugs, including protease inhibitors, ucleosides and non-nucleoside polymerization in recent years Enzyme inhibitor and NS5A inhibitor etc..There are three the protease inhibitors class drugs of FDA approval: VX-950 (Telaprevir), the shortcomings that SCH-503034 (Boceprevir) and TMC435 (Simeprevir), protease inhibitors is It is also easy to produce that mutation, toxicity is big, poor bioavailability, it is effective to a other gene type.Egg of the Telaprevir as the first generation White enzyme inhibitor has logged out market.The second generation of high activity and wide spectrum and third generation protease inhibitors is mainly used as and other One of the component of drug combination of hepatitis drug.
The hepatitis C drug Suo Feibuwei (trade name: Sovaldi, common name: Sofosbuvir) of lucky Leadd B.V Acquisition U.S. Food and Drug Administration on December 6 (FDA) approval in 2013 is used for chronic hepatitis C (HepatitisC) The treatment of adult patient.Suo Feibuwei is the first granted drug that can be used for the full oral treatment regimes of hepatitis C, for spy When determining the treatment of genotype (2 types, 3 types) chronic hepatitis C, the demand to conventional injection interfering effects of drug plain (IFN) can be eliminated.
But since bioavilability is low in vivo by sofosbuvir, need with biggish dosage, hepatitis patient need Receive long-term treatment, bring virus drug resistance and long-term safety problem can not be ignored therewith, therefore, develop new biology The HCV infection therapeutic agent that availability is high and longer half-life period, drug effect are high is still clinical urgent need.
Summary of the invention:
The purpose of the present invention is the structures to nucleoside phosphorylase long-chain ester analogs to be further transformed, and is had The active novel nucleoside phosphate analogs of more high bioavilability, more hypotoxicity and more highly resistance HCV virus, deeply to grind from now on Study carefully and lays the foundation with the antiviral application of exploitation the compounds of this invention.
To solve the above problems, the technical solution adopted by the present invention are as follows:
The present invention provides the compound with general formula structure (Ia), salt, tautomer or free alkalis
Wherein, Base is B1, B2, B3, B4, B5；
Here, R1、R2、R3、R4、R5It is H, D, F, Cl, CH each independently3、NH2Or cyclopropylamino.
Ri is five yuan of ribose Ri1、Ri2、Ri3；
Here, X2、Y2、X3、Y3、Y4It is H, F, Cl, OH, CH each independently3Or N3。
Z1=O, C=CH2；
Z2=O, CH2；
Z3、Z4It is O or S each independently；
X, Y is H or D each independently；
M=0-4, n=14-16；
Rb=R0, R1, R4；
Here, R0=H, C1- C6Alkyl；R1=CH2(CH2)mCH2OCH2(CH2)nCH3；
R4=aryl.
As further preferred scheme, compound (Ia) of the present invention, salt, tautomer or free alkali, It is preferred that R0=H；It is preferred that combination or the m=0 of m=1, n=14, the combination of n=16；It is preferred that R4=phenyl.
As further preferred scheme, compound of the present invention, salt, tautomer or free alkali, phosphorus original Son is chiral atom, preferably its single configuration S(P)Configuration or R(P)Configuration or S(P)Configuration and R(P)The mixing of configuration any proportion Object.
As scheme still more preferably, compound of the present invention, salt, tautomer or free alkali, institute Preferred structural formula of compound is as follows:
Nucleoside phosphorylase long-chain ester compounds of the present invention, synthetic route are as follows:
Here: Base, Ri, X, Y, m, n, RbDefinition is the same as claim 1.
Under alkaline condition, R is added with after phosphorus oxychloride reaction in K1bOH reaction, adds Pentafluorophenol reaction Close object F1B-1 and F1B-2；Under cryogenic, F1B-2 and F1B-1 are reacted with nucleosides, respectively obtain compound N 1B-1 Or N1B-2.
Nucleoside phosphorylase long-chain ester compounds of the present invention, with pharmaceutically acceptable carrier, diluent or excipient It is prepared by mixing into pharmaceutical preparation and nanometer formulation, to be suitable for oral or parenteral；Medication includes, but are not limited to In intradermal, intramuscular, peritonaeum, intravenous, subcutaneous, intranasal and peroral route.
The present invention provides a kind of medical compositions of nucleoside phosphorylase long-chain ester compounds comprising compound (Ia).
Medical composition of the present invention also contains the other therapeutic agents independently selected from following drug: Ribavirin (Ribavirin), interferon, hepatitis NS3 protease inhibitors, HCV reverse transcriptase NS5B non-nucleosidic inhibitors, HCV reverse transcription Enzyme NS5B nucleosidic inhibitors, the synergist of NS5A inhibitor and NS5A inhibitor, entry inhibitor, cyclosporine immunosupress Agent, NS4A antagonist, NS4B inhibitor, cyclophilin inhibitor.
Nucleoside phosphorylase long-chain ester compounds and its Pharmaceutical composition of the present invention are preparing anti-Flaviviridae Application in drug, the flaviviridae are Hepatitis C Virus.
The dosage form of pharmaceutical composition of the present invention is tablet, injection or capsule.
Specific embodiment
The present invention is further elaborated by the following examples, but the present invention is not limited to these Examples.This hair Reagent used in bright embodiment and raw material are the commercially available gained in market.
Embodiment 1
(S) -3- (hexadecane epoxide) propyl pentafluorophenyl group phosphate (FP011-1) and (R) -3- (hexadecane oxygen Base) propyl pentafluorophenyl group phosphate (FP011-2) synthesis.
Phosphorus oxychloride (5g, 3.04ml, 32.6mmol) is added in reaction flask, adds acetonitrile 200mL, is cooled to -70 DEG C, Acetonitrile (60mL) solution of K11 (9.8g, 32.6mmol) and triethylamine (3.3 grams, 4.53ml, 32.6mmol) is slowly added dropwise, drips It adds complete, is slowly increased to room temperature, after reaction overnight, is cooled to 0 DEG C, by Pentafluorophenol (5.4g, 29.4mmol) and triethylamine The acetonitrile solution 60mL liquid of (7.3 grams, 10ml, 72mmol) is added drop-wise in above-mentioned solution, is stirred 1 hour at 0 DEG C, is risen to room Temperature after being stirred overnight, is added 100ml methylene chloride and 100ml water, separates organic phase, dense with depressurizing after anhydrous sodium sulfate drying Contracting, residue obtain 8.5g white solid, 10% tert-butyl of solid with silica gel post separation (0-30% ethyl acetate/n-hexane) Methyl ether/n-hexane recrystallization, obtains white solid FP011-2 (3.4g), mother liquor with silica gel post separation (50% ethyl acetate/oneself Alkane) FP011-1 (2.5g) and FP011-2 (0.4g), FP011-2 and FP011-1 purity are all larger than 99%.
FP011-1:1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.08-1.39 (26H, m, 13 ×CH2), 1.45-1.61 (2H, m, CH2), 1.81-1.95 (2H, m, CH2), 3.30-3.50 (4H, m, 2 × OCH2), 3.85-4.00 (2H, m, OCH2)。
31P NMR (162MHz, CDCl3) δ -1.66.
FP011-2:1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.11-1.42 (26H, m, 13 ×CH2), 1.47-1.64 (2H, m, CH2), 1.84-1.99 (2H, m, CH2), 3.33-3.53 (4H, m, 2 × OCH2), 3.87-4.04 (2H, m, OCH2)。
31P NMR (162MHz, CDCl3) δ -1.92.
Embodiment 2
(S) -2- (octadecane epoxide) ethyl pentafluorophenyl group phosphate (FP012-1) and (R) -2- (octadecane oxygen Base) ethyl pentafluorophenyl group phosphate (FP012-2) synthesis.
FP012-1 and FP012-2 is synthesized in the similar method of embodiment 1
FP012-1:1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.07-1.41 (30H, m, 15 ×CH2), 1.46-1.62 (2H, m, CH2), 3.32-3.48 (4H, m, 2 × OCH2), 3.85-3.99 (2H, m, OCH2)。
31P NMR (162MHz, CDCl3) δ -1.77.
FP012-2:1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.09-1.44 (30H, m, 15 ×CH2), 1.49-1.66 (2H, m, CH2), 3.35-3.50 (4H, m, 2 × OCH2), 3.87-4.04 (2H, m, OCH2)。
31P NMR (162MHz, CDCl3) δ -2.06.
Embodiment 3
The synthesis of two (3- (hexadecane epoxide) propyl) pentafluorophenyl group phosphates (FP11).
Phosphorus oxychloride (5g, 3.04ml, 32.6mmol) is added in reaction flask, adds acetonitrile 200mL, is cooled to -70 DEG C, Acetonitrile (60mL) solution of K11 (19.6g, 65.2mmol) and triethylamine (6.6g, 9.06ml, 65.2mmol) is slowly added dropwise, drips It adds complete, is slowly increased to room temperature, after reaction overnight, is cooled to 0 DEG C, by Pentafluorophenol (5.4g, 29.4mmol) and triethylamine The acetonitrile solution 60mL liquid of (7.3 grams, 10ml, 72mmol) is added drop-wise in above-mentioned solution, is stirred 1 hour at 0 DEG C, is risen to room Temperature after being stirred overnight, is added 100 milliliters of methylene chloride and 100 milliliters of water, separates organic phase, subtracts after being dried with anhydrous sodium sulfate Pressure concentration, residue obtain 13.1g white solid, 10% tertiary fourth of solid with silica gel post separation (0-30% ethyl acetate/hexane) Ylmethyl ether/hexane recrystallization, obtains white solid FP11 (5.2g), and mother liquor is with silica gel post separation (50% ethyl acetate/hexane) FP11 (4.1g) again, FP11 purity are greater than 99%.
FP11:1H NMR (400MHz, CDCl3) δ (ppm): 0.89 (6H, dt, 2 × CH3), 1.08-1.40 (52H, m, 26 ×CH2), 1.45-1.63 (4H, m, 2 × CH2), 1.81-1.97 (4H, m, 2 × CH2), 3.30-3.53 (8H, m, 4 × OCH2), 3.85-4.03 (4H, m, 2 × OCH2)。
Embodiment 4
(R) -3- (hexadecane epoxide) propyl pentafluorophenyl group phenyl phosphate ester (FP14-1) and (S) -3- (hexadecane Oxygroup) propyl pentafluorophenyl group phenyl phosphate ester (FP14-2) synthesis.
Dichloro-phenyl phosphate (6.88g, 3.04ml, 32.6mmol) is added in reaction flask, adds acetonitrile 200mL, it is cooling To -70 DEG C, the acetonitrile of K11 (9.8g, 32.6mmol) and triethylamine (3.3 grams, 4.53ml, 32.6mmol) is slowly added dropwise (60mL) solution, is added dropwise, and is slowly increased to room temperature, after reaction overnight, is cooled to 0 DEG C, by Pentafluorophenol (5.4g, It 29.4mmol) is added drop-wise in above-mentioned solution with the acetonitrile solution 60mL liquid of triethylamine (7.3 grams, 10ml, 72mmol), at 0 DEG C Stirring 1 hour, is warmed to room temperature, after being stirred overnight, 100 milliliters of methylene chloride and 100 milliliters of water is added, organic phase are separated, with nothing It is concentrated under reduced pressure after aqueous sodium persulfate is dry, residue obtains 11.2g white with silica gel post separation (0-30% ethyl acetate/hexane) and consolidates Body, solid are recrystallized with 10% t-butyl methyl ether/hexane, are obtained white solid FP14-2 (4.5g), mother liquor silica gel post separation (50% ethyl acetate/hexane) obtains FP14-1 (3.3g) and FP14-2 (0.5g), FP14-2 and FP14-1 purity are all larger than 99%.
FP14-1:1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.08-1.39 (26H, m, 13 ×CH2), 1.45-1.61 (2H, m, CH2), 1.81-1.95 (2H, m, CH2), 3.31-3.49 (4H, m, 2 × OCH2), 3.85-4.03 (2H, m, OCH2), 7.22-7.31 (2H, m, the H on phenyl ring ortho position), 7.31-7.41 (3H, m, it is right between phenyl ring H on position).
31P NMR (162MHz, CDCl3) δ -2.03.
FP14-1:1H NMR (400MHz, CDCl3) δ (ppm): 0.89 (3H, t, CH3), 1.10-1.42 (26H, m, 13 ×CH2), 1.48-1.62 (2H, m, CH2), 1.83-1.99 (2H, m, CH2), 3.33-3.53 (4H, m, 2 × OCH2), 3.88-4.04 (2H, m, OCH2), 7.25-7.36 (2H, m, the H on phenyl ring ortho position), 7.38-7.46 (3H, m, it is right between phenyl ring H on position).
31P NMR (162MHz, CDCl3) δ -2.36.
Embodiment 5
(S)-[(3- (hexadecane epoxide) propyl) (((2R, 3R, 4R, 5R) -5- (2,4 (1H, 3H)-pyrimidines two Ketone -1- base) the fluoro- 3- hydroxy-4-methyl tetrahydrofuran -2- base of -4-) methyl)] phosphate (SOF011-1) Synthesis
Nucleosides SOF (260.2mg, 1mmol) and the anhydrous THF of 5.0mL are added into 50mL flask, mixture is in ice-water bath It is cooled to 0 DEG C.It is added dropwise tert-butyl magnesium chloride 1.0MinTHF solution (3.0mL, 3.0mmol), reaction mixture stirs at 0 DEG C The solution of phosphorus reagent FP011-2 (874.5mg, 1.6mmol) in 5mL THF is then added dropwise in 30min at 0 DEG C.By gained To clarifying reaction solution be warmed to room temperature, stirring 20 hours after, be added saturation NH4Cl (15mL) is stirred 5 minutes, by mixture It is diluted with ethyl acetate (200mL), separates organic phase, aqueous layer with ethyl acetate (30mL) is extracted twice.Combined organic layer is used Water (30mL), saturation NaHCO3The washing of (2x30mL), salt water (30mL), and through Na2SO4Decompression boils off solvent, residue after drying It purifies, obtains white solid product SOF011-1 (305.3mg) via silica gel column chromatography (methylene chloride of 0-10% methanol), receive Rate 49%).
SOF011-1:1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.08-1.39 (29H, m, 13×CH2andCH3), 1.45-1.61 (2H, m, CH2), 1.81-1.95 (2H, m, CH2), 3.30-3.50 (4H, m, 2 × OCH2), 3.85-3.99 (2H, m, OCH2), 4.08-4.19 (1H, m, the H on saccharide ring 3 '-position), 4.27 (1H, brs, saccharide rings OH on 3 '-positions), 4.34-4.41 (1H, m, the H on saccharide ring 4 '-position), 4.46-4.52 (2H, m, on saccharide ring 5 '-position H), 5.58-5.72 (1H, d, the H on pyrimidine ring 5), 6.18 (1H, s, the H on saccharide ring 1 '-position), 7.21-7.51 (1H, D, the H on pyrimidine ring 6), 9.74 (1H, s, the NH on pyrimidine ring 3).
31P NMR (162MHz, CDCl3)δ3.25；
ESI+MS:(M+H)+623.4。
Embodiment 6
(R)-[(3- (hexadecane epoxide) propyl) (((2R, 3R, 4R, 5R) -5- (2,4 (1H, 3H)-pyrimidines two Ketone -1- base) the fluoro- 3- hydroxy-4-methyl tetrahydrofuran -2- base of -4-) methyl)] phosphate (SOF011-2) Synthesis
SOF011-2 is synthesized in the similar method of embodiment 5.
SOF011-1:1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.10-1.41 (29H, m, 13×CH2andCH3), 1.48-1.64 (2H, m, CH2), 1.84-1.97 (2H, m, CH2), 3.33-3.51 (4H, m, 2 × OCH2), 3.87-4.03 (2H, m, OCH2), 4.11-4.20 (1H, m, the H on saccharide ring 3 '-position), 4.27 (1H, brs, saccharide rings OH on 3 '-positions), 4.37-4.46 (1H, m, the H on saccharide ring 4 '-position), 4.49-4.54 (2H, m, on saccharide ring 5 '-position H), 5.59-5.73 (1H, d, the H on pyrimidine ring 5), 6.18 (1H, s, the H on saccharide ring 1 '-position), 7.22-7.53 (1H, D, the H on pyrimidine ring 6), 9.74 (1H, s, the NH on pyrimidine ring 3).
31P NMR (162MHz, CDCl3)δ3.56；
ESI+MS:(M+H)+623.4。
Embodiment 7
(S)-[(2- (octadecane epoxide) ethyl) (((2S, 3S, 5R) -5- (5- methyl -2,4 (1H, 3H)-phonetic Pyridine diketone -1- base) -3- nitrine tetrahydrofuran -2- base) methyl)] synthesis of phosphate (AZT012-1).
AZT012-1 is synthesized in the similar method of embodiment 5.
1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.07-1.41 (30H, m, 15 × CH2), 1.46-1.62 (2H, m, CH2), 1.89-1.99 (3H, d, the CH on pyrimidine ring 53), 2.29-2.53 (3H, m, saccharide ring The H on 3 '-position of Hand saccharide ring on 2 '-positions), 3.32-3.48 (5H, m, 2 × OCH2H on 4 '-position of and saccharide ring), 3.85-4.01 (4H, m, OCH2H on 5 '-position of and saccharide ring), 6.15 (1H, t, the H on saccharide ring 1 '-position), 7.25 (1H, s, H on pyrimidine ring 6), 9.25 (1H, s, the NH on pyrimidine ring 3).
31P NMR (162MHz, CDCl3)δ3.46；
ESI+MS:(M+H)+644.7。
Embodiment 8
(R)-[(2- (octadecane epoxide) ethyl) (((2S, 3S, 5R) -5- (5- methyl -2,4 (1H, 3H)-phonetic Pyridine diketone -1- base) -3- nitrine tetrahydrofuran -2- base) methyl)] synthesis of phosphate (AZT012-2).
AZT012-2 is synthesized in the similar method of embodiment 5.
1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.09-1.44 (30H, m, 15 × CH2), 1.49-1.64 (2H, m, CH2), 1.91-2.00 (3H, d, the CH on pyrimidine ring 53), 2.31-2.54 (3H, m, saccharide ring The H on 3 '-position of Hand saccharide ring on 2 '-positions), 3.34-3.50 (5H, m, 2 × OCH2H on 4 '-position of and saccharide ring), 3.87-4.03 (4H, m, OCH2H on 5 '-position of and saccharide ring), 6.15 (1H, t, the H on saccharide ring 1 '-position), 7.25 (1H, s, H on pyrimidine ring 6), 9.25 (1H, s, the NH on pyrimidine ring 3).
31P NMR (162MHz, CDCl3)δ3.76；
ESI+MS:(M+H)+644.7。
Embodiment 9
[(((2R, 5S) -5- (fluoro- -2 (1H)-pyrimidone -1- base of 4- amino of 5-) -1,3- oxygen thia ring Pentane -2- base) methoxyl group) (two (3- (hexadecane epoxide) propyl))] and phosphate (FTC11) synthesis.
FTC11 is synthesized in the similar method of embodiment 5.
1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (6H, dt, 2 × CH3), 1.08-1.38 (52H, m, 26 × CH2), 1.45-1.60 (4H, m, 2 × CH2), 1.81-1.94 (4H, m, 2 × CH2), 3.30-3.49 (10H, m, 4 × OCH2H on 2 '-position of and saccharide ring), 3.85-3.99 (4H, m, 2 × OCH2), 4.25-4.46 (1H, m, on saccharide ring 4 '-position H), 5.28-5.41 (2H, m, the H on saccharide ring 5 '-position), 5.57-5.69 (1H, m, the H on saccharide ring 1 '-position), 5.80- 6.20 (2H, dbrs, the NH on pyrimidine ring 42), 7.91 (1H, s, the H on pyrimidine ring 6).
ESI+MS:(M+H)+893.2。
Embodiment 10
(S)-[(((2R, 5S) -5- (4- amino -2 (1H)-pyrimidone -1- base) -1,3- oxygen sulphur Polymorphs Alkane -2- base) methyl) (3- (hexadecane epoxide) propyl) (phenyl)] and phosphate (3TC14-1) synthesis.
3TC14-1 is synthesized in the similar method of embodiment 5.
1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.08-1.39 (26H, m, 13 × CH2), 1.45-1.61 (2H, m, CH2), 1.81-1.95 (2H, m, CH2), 3.05-3.51 (6H, m, the Hand2 on saccharide ring 2 '-position ×OCH2), 3.85-4.00 (2H, m, OCH2), 4.25-4.47 (1H, m, the H on saccharide ring 4 '-position), 5.28-5.42 (3H, M, the H on Hand pyrimidine ring 5 on saccharide ring 5 '-position), 5.62 (1H, s, the H on saccharide ring 1 '-position), 5.80-6.21 (2H, Dbrs, the NH on pyrimidine ring 42), 7.22-7.29 (2H, m, the H on phenyl ring ortho position), 7.31-7.39 (3H, m, between phenyl ring H in contraposition), 8.31-8.72 (1H, d, the H on pyrimidine ring 6).
31P NMR (162MHz, CDCl3)δ3.92；
ESI+MS:(M+H)+668.8。
Embodiment 11
(R)-[(((2R, 5S) -5- (4- amino -2 (1H)-pyrimidone -1- base) -1,3- oxygen sulphur Polymorphs Alkane -2- base) methyl) (3- (hexadecane epoxide) propyl) (phenyl)] and phosphate (3TC14-2) synthesis.
3TC14-2 is synthesized in the similar method of embodiment 5.
1H NMR (400MHz, CDCl3) δ (ppm): 0.88 (3H, t, CH3), 1.11-1.41 (26H, m, 13 × CH2), 1.48-1.63 (2H, m, CH2), 1.84-1.98 (2H, m, CH2), 3.09-3.51 (6H, m, the Hand2 on saccharide ring 2 '-position ×OCH2), 3.88-4.03 (2H, m, OCH2), 4.27-4.49 (1H, m, the H on saccharide ring 4 '-position), 5.30-5.45 (3H, M, the H on Hand pyrimidine ring 5 on saccharide ring 5 '-position), 5.63 (1H, s, the H on saccharide ring 1 '-position), 5.82-6.24 (2H, Dbrs, the NH on pyrimidine ring 42), 7.24-7.31 (2H, m, the H on phenyl ring ortho position), 7.32-7.42H, m are right between phenyl ring H on position), 8.33-8.73 (1H, d, the H on pyrimidine ring 6).
31P NMR (162MHz, CDCl3)δ4.22；
ESI+MS:(M+H)+668.8。
Embodiment 12
Biological assessment
1. antiviral activity detection of the compound of the present invention in HCV replicon (HCVpp) system
HCV replicon mensuration program
General procedure: make the cell in the source Huh-7 with HCV genotype 1b replicon and luciferase reporter gene It is (Zluc) in supplement 10% fetal calf serum, 2mM GlutaMAX, 1%MEM nonessential amino acid, 100IU/mL penicillin, 100 The Dulbecco of μ g/mL streptomysin and 0.5mg/mL (G418) improve growth in Eagle culture medium (DMEM).By using being based on Lipid/histone transfection process transiently transfects Zluc cell with mankind's carbonyl acid ester enzyme 1 (CES1).After transfection 24 and 48 hours, Using anti-CES1 and anti-tag antibody, the expression of CES1 is confirmed by Western blotting (Westernblot).For dose response Test, with 7.5xl03 cells/well, in 50 μ L volumes, by cell inoculation in 96 orifice plates, and in 37 DEG C/5%CO2Under incubate It educates.Fresh drug solution is as 2X liquid storage in Huh-7 culture medium.From these liquid storage systems in the DMEM without G418 Standby 10 5 times of other dilutions.At least 3 hours after being inoculated with Huc cell, by the medicine that 50 μ L are added in duplicate into plate Object dilution is to start drug-treated.The range of drug final concentration is 100nM-0.0000512n Μ.Then by cell 37 DEG C/5%CO2Lower incubation.Or compound is tested with two kinds of concentration (10nM and 100nM).In all cases, Huh-7 (its Not with HCV replicon) it is used as negative control.After being incubated for 72 hours, Fluc is passed through for 5 '-by quantization Fluorine luciferin list oxygen synthesizes the photon that oxygroup fluorine luciferin (oxyfIuoroluciferin) is emitted, to measure HCV duplication Inhibition.For this purpose, removing culture medium from plate by tapping, 50 microlitres of ONE-glo luciferase assay kits are added each Hole.Plate is gently vibrated 3 minutes at room temperature, using 700nm cut-off filter, there is 1 second readout time It measures and shines on Victor3V1420 multiple labeling counter (PerkinElmer).Pass through Microsoft Excel and XLfit4.1 The dose-effect curve for the gained best fit equation formula that software is found out calculates EC50Value.
For Cytotoxic evaluation, Zluc cell is handled with above compound, is deposited using CellTiter-Blue cell Vitality test method (Promega) 20 μ L measurement solution is added in each hole, to monitor cell viability.Then by plate 37 DEG C/ 5%CO2It is lower to be incubated at least 3 hours.Respectively with the excitation and launch wavelength of 560 and 590nm, remember in Victor3V1420 multiple labeling The fluorescence of detection plate, finds out CC using Microsoft Excel and XLfit4.1 software in number device (Perkin Elmer)50Value.
The compound that following table provides is measured according to above-mentioned replicon measuring method.
+++ indicate 1-10nM；++ indicate 10-100nM；+ indicate 0.1-1 μM；
* Suo Feibuwei is according to bibliography J.Org.Chem.2011,76,8311 preparations

Claims (10)

1. the compound with structure (Ia), salt, tautomer or free alkali
Wherein, Base is B1, B2, B3, B4, B5；
Here, R1、R2、R3、R4、R5It is H, D, F, Cl, CH each independently3、NH2Or cyclopropylamino；
Ri is five yuan of ribose Ri1、Ri2、Ri3；
Here, X2、Y2、X3、Y3、Y4It is H, F, Cl, OH, CH each independently3Or N3；
Z1=O, C=CH2；
Z2=O, CH2；
Z3、Z4It is O or S each independently；
X, Y is H or D each independently；
M=0-4, n=14-16；
Rb=R0, R1, R4；
Here, R0=H, C1- C6Alkyl；R1=CH2(CH2)mCH2OCH2(CH2)nCH3；
R4=aryl.
2. compound (Ia) as described in claim 1, salt, tautomer or free alkali, which is characterized in that preferred R0= H；It is preferred that combination or the m=0 of m=1, n=14, the combination of n=16；It is preferred that R4=phenyl.
3. such as compound claimed in claims 1-2, salt, tautomer or free alkali, which is characterized in that phosphorus atoms are Chiral atom, preferably its single configuration S(P)Configuration or R(P)Configuration or S(P)Configuration and R(P)The mixture of configuration any proportion.
4. the compound as described in claim 1-3, salt, tautomer or free alkali, which is characterized in that institute is preferred Structural formula of compound is as follows:
5. a kind of method for preparing nucleoside phosphorylase long-chain ester compounds described in claim 1-4, which is characterized in that the side The synthetic route of method is as follows:
Here: Base, Ri, X, Y, m, n, RbDefinition is the same as claim 1；
Under alkaline condition, R is added with after phosphorus oxychloride reaction in K1bOH reaction, adds Pentafluorophenol and reacts to obtain compound F1B-1 and F1B-2；Under cryogenic, F1B-2 and F1B-1 are reacted with nucleosides, respectively obtain compound N 1B-1 or N1B-2.
6. nucleoside phosphorylase long-chain ester compounds described in -4 according to claim 1, it is characterized in that: with pharmaceutically acceptable load Body, diluent or excipient are prepared by mixing into pharmaceutical preparation and nanometer formulation, to be suitable for oral or parenteral；Administration Method includes, but are not limited in intradermal, intramuscular, peritonaeum, intravenous, subcutaneous, intranasal and peroral route.
7. a kind of medical composition comprising nucleoside phosphorylase long-chain ester compounds described in claim 1.
8. medical composition according to claim 7, it is characterized in that: also containing the other treatment independently selected from following drug Agent: the non-nucleosides of Ribavirin (Ribavirin), interferon, hepatitis NS3 protease inhibitors, HCV reverse transcriptase NS5B inhibits Agent, HCV reverse transcriptase NS5B nucleosidic inhibitors, NS5A inhibitor and NS5A inhibitor synergist, entry inhibitor, ring spore Plain immunosuppressor, NS4A antagonist, NS4B inhibitor, cyclophilin inhibitor.
9. a kind of nucleoside phosphorylase long-chain ester compounds described in claim 1 and its Pharmaceutical composition are preparing anti-flavivirus section disease Application in the drug of poison, it is characterized in that: the flaviviridae is Hepatitis C Virus.
10. the pharmaceutical composition as described in claim 7-9, it is characterised in that: the dosage form of described pharmaceutical composition be tablet, Injection or capsule.
CN201811577370.6A 2018-12-21 2018-12-21 With the active nucleoside phosphorylase long-chain ester analogs of suppressing virus replication, preparation method and its medicinal usage Pending CN109503688A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811577370.6A CN109503688A (en) 2018-12-21 2018-12-21 With the active nucleoside phosphorylase long-chain ester analogs of suppressing virus replication, preparation method and its medicinal usage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811577370.6A CN109503688A (en) 2018-12-21 2018-12-21 With the active nucleoside phosphorylase long-chain ester analogs of suppressing virus replication, preparation method and its medicinal usage

Publications (1)

Publication Number Publication Date
CN109503688A true CN109503688A (en) 2019-03-22

Family

ID=65754344

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811577370.6A Pending CN109503688A (en) 2018-12-21 2018-12-21 With the active nucleoside phosphorylase long-chain ester analogs of suppressing virus replication, preparation method and its medicinal usage

Country Status (1)

Country Link
CN (1) CN109503688A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102137676A (en) * 2007-12-27 2011-07-27 伊皮芬尼生物科学公司 Antiviral compounds
TW201542581A (en) * 2013-09-11 2015-11-16 Univ Emory Nucleotide and nucleoside therapeutic compositions and uses related thereto
CN108276463A (en) * 2017-01-06 2018-07-13 米文君 A new class of compound and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102137676A (en) * 2007-12-27 2011-07-27 伊皮芬尼生物科学公司 Antiviral compounds
TW201542581A (en) * 2013-09-11 2015-11-16 Univ Emory Nucleotide and nucleoside therapeutic compositions and uses related thereto
CN108276463A (en) * 2017-01-06 2018-07-13 米文君 A new class of compound and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STEVEN D. DONG，ET AL.: "Synthesis and evaluation of a new phosphorylated ribavirin prodrug", 《ANTIVIRAL RESEARCH》 *
寿雪枫等: "抗丙型肝炎药物索磷布韦的设计合成研究进展", 《国际药学研究杂志》 *

Similar Documents

Publication Publication Date Title
TWI593700B (en) A prodrug of tenofovir and medical use thereof
US20210052613A1 (en) Methods for treating filoviridae virus infections
CN104672288B (en) A kind of deuterated Suo Feibuwei and application thereof
TWI515000B (en) Compounds and pharmaceutical compositions for the treatment of viral infections
RU2519947C2 (en) Compounds and pharmaceutical compositions for treatment of viral diseases
CN102241604B (en) Amino acid modified curcumin, synthesis method thereof, and application thereof
AU2015317972B2 (en) Nucleotide analogs
JP2020534361A (en) Substituted nucleosides, nucleotides, and analogs thereof
IL250389A (en) Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
EA027929B1 (en) Uracyl spirooxetane nucleosides
CA2818853A1 (en) 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EP2828277A1 (en) Solid forms of a thiophosphoramidate nucleotide prodrug
CN108473477A (en) The pyrimidine of aryl substitution for being used in influenza infection
CN104039774A (en) Hcv ns3 protease inhibitors
CN104761604A (en) Uridine monophosphate analogue, and preparation method and applications thereof
KR20070106578A (en) Anti-cancer and anti-microbial oxazolidinones and analogues
CN109651452A (en) With the active nucleoside phosphorylase long-chain dibasic acid esters analog of suppressing virus replication, preparation method and its medicinal usage
CN101511185A (en) Azole nucleosides and use as inhibitors of RNA and DNA varial polymerases
CN108350008B (en) Novel acyclic nucleoside analogue and pharmaceutical composition thereof
CN109627272A (en) With the active nucleotide phosphate of suppressing virus replication similar to object, preparation method and its medicinal usage
EP4051679A1 (en) Condensed pyridazine or pyrimidine as btk inhibitors
CN109503688A (en) With the active nucleoside phosphorylase long-chain ester analogs of suppressing virus replication, preparation method and its medicinal usage
CN109651468A (en) With the active nucleoside phosphoramidate analog of suppressing virus replication, preparation method and its medicinal usage
Liu et al. Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity
CN112194694B (en) Urodylate phenylpropionate phosphoramidate compound, pharmaceutical composition thereof, and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination